EU Approves Shire's Vpriv For Gaucher Disease, As Shortages Of Genzyme's Rival Product Ease
Shire's Vpriv gains approval in 30 European countries for Gaucher disease, but competition from rival products looks set to increase.
Shire's Vpriv gains approval in 30 European countries for Gaucher disease, but competition from rival products looks set to increase.